Clinical Trials Browser

Phase 3 × INDUSTRY × Bortezomib × Clear all

NCT05083169 2026-03-18

MajesTEC-3

Phase 3 Active not recruiting

587 enrolled 1 FDA

Multiple Myeloma

NCT04504825 2026-03-17

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

Phase 3 Active not recruiting

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT04512235 2026-03-17

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

Phase 3 Active not recruiting

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT04181827 2026-03-16

CARTITUDE-4

Phase 3 Active not recruiting

419 enrolled 10 charts

Multiple Myeloma

NCT04923893 2026-03-13

CARTITUDE-5

Phase 3 Active not recruiting

Multiple Myeloma

NCT06158841 2026-03-13

CERVINO

Phase 3 Recruiting

Multiple Myeloma

NCT06208150 2026-03-13

MonumenTAL-6

Phase 3 Recruiting

Multiple Myeloma

NCT05519085 2026-03-11

SUCCESSOR-1

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT06152575 2026-02-03

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Phase 3 Recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT07297329 2026-01-29

A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Phase 3 Recruiting

Multiple Myeloma

NCT03652064 2026-01-20

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Phase 3 Active not recruiting

395 enrolled 1 FDA

Multiple Myeloma

NCT02136134 2025-08-29

Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3 Completed

498 enrolled 15 charts

Multiple Myeloma, Plasmacytoma

NCT02195479 2025-08-22

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

Phase 3 Completed

706 enrolled 29 charts

Multiple Myeloma

NCT06464991 2025-07-20

FUMANBA-03

Phase 3 Recruiting

Multiple Myeloma

NCT04975997 2025-07-10

EXCALIBER-RRMM

Phase 3 Active not recruiting

Multiple Myeloma

NCT06956170 2025-06-11

DREAMM 8

Phase 3 Active not recruiting

21 enrolled 9 charts

Multiple Myeloma

NCT06868667 2025-05-09

DREAMM 7

Phase 3 Active not recruiting

24 enrolled 10 charts

Multiple Myeloma

NCT04484623 2025-03-18

DREAMM 8

Phase 3 Active not recruiting

302 enrolled 10 charts

Multiple Myeloma

NCT01539083 2025-02-04

VCAT

Phase 3 Completed

256 enrolled 13 charts

Multiple Myeloma

NCT03319667 2024-11-27

IMROZ

Phase 3 Active not recruiting

475 enrolled 1 FDA

Multiple Myeloma

NCT04246047 2024-10-24

DREAMM 7

Phase 3 Active not recruiting

494 enrolled 10 charts 1 FDA

Multiple Myeloma

NCT03110562 2024-08-21

BOSTON

Phase 3 Completed

402 enrolled 22 charts 2 FDA

Multiple Myeloma, Recurrence

NCT03234972 2024-05-29

A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma

Phase 3 Completed

Multiple Myeloma

NCT03217812 2024-04-25

A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)

Phase 3 Completed

Multiple Myeloma

NCT02755597 2023-08-22

Bellini

Phase 3 Completed

291 enrolled 24 charts

Multiple Myeloma

NCT03651128 2022-12-15

KarMMa-3

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT00773747 2021-04-30

Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)

Phase 3 Completed

637 enrolled 15 charts

LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT01023308 2020-03-17

PANORAMA-1

Phase 3 Completed

767 enrolled 17 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT02811978 2019-11-08

Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple Myeloma

Phase 3 Completed

Multiple Myeloma

NCT01818752 2019-08-26

CLARION

Phase 3 Completed

955 enrolled 20 charts

Multiple Myeloma

NCT01470131 2018-12-19

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

Phase 3 Terminated

Multiple Myeloma, Recurrence

NCT00722137 2018-07-12

Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma

Phase 3 Completed

487 enrolled 20 charts

Lymphoma, Mantle-Cell

NCT01002248 2018-02-09

Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients

Phase 3 Terminated

Multiple Myeloma

NCT01910987 2017-02-17

OPTIMRETREAT

Phase 3 Completed

Multiple Myeloma

NCT00103506 2015-10-19

Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma

Phase 3 Completed

646 enrolled 10 charts

Multiple Myeloma

NCT00416273 2015-03-06

A Study of Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma

Phase 3 Completed

Multiple Myeloma

NCT00416208 2015-03-05

Consolidation Therapy With Bortezomib in Elderly Patients With Multiple Myeloma

Phase 3 Completed

Multiple Myeloma

NCT00813150 2014-08-15

Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma

Phase 3 Completed

96 enrolled 12 charts

Multiple Myeloma, Neoplasms

NCT00507416 2014-05-01

UPFRONT

Phase 3 Completed

502 enrolled 17 charts

Multiple Myeloma

NCT01801436 2013-05-16

A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma

Phase 3 Completed

14 enrolled 34 charts

Multiple Myeloma

NCT00048230 2012-01-13

PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Phase 3 Completed

Multiple Myeloma

NCT00063726 2012-01-13

A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039

Phase 3 Completed

Multiple Myeloma

NCT00546780 2011-06-28

BMS TIME-1

Phase 3 Completed

Multiple Myeloma

NCT00111319 2009-03-26

VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma

Phase 3 Completed

Multiple Myeloma